Global Anti-VEGF Therapies Market Growth (Status and Outlook) 2026-2032

July 2026 | 81 pages | ID: GB4C80F61E6BEN
LP Information

Abstracts

The global Anti-VEGF Therapies market size is predicted to grow from US$ 942 million in 2025 to US$ 1455 million in 2032; it is expected to grow at a CAGR of 6.5% from 2026 to 2032.

Angiogenesis, the generation of new blood vessels, is an essential physiological process that can be dysregulated in various pathological conditions, including cancer. The vascular endothelial growth factor (VEGF) pathway is considered the most important and is a well-characterized contributor to angiogenesis. VEGF-A and other members of the VEGF family such as placental growth factor (PlGF) are upregulated in pathological conditions. VEGF-A, the first VEGF characterized, has served as a paradigm for the development of antiangiogenesis as a therapeutic strategy.

United States market for Anti-VEGF Therapies is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Anti-VEGF Therapies is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Anti-VEGF Therapies is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Anti-VEGF Therapies players cover Roche, Eli Lilly, Pfizer, Regeneron Pharmaceuticals, Novartis, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LPI (LP Information)' newest research report, the ?Anti-VEGF Therapies Industry Forecast? looks at past sales and reviews total world Anti-VEGF Therapies sales in 2025, providing a comprehensive analysis by region and market sector of projected Anti-VEGF Therapies sales for 2026 through 2032. With Anti-VEGF Therapies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-VEGF Therapies industry.

This Insight Report provides a comprehensive analysis of the global Anti-VEGF Therapies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Anti-VEGF Therapies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Anti-VEGF Therapies market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-VEGF Therapies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-VEGF Therapies.

This report presents a comprehensive overview, market shares, and growth opportunities of Anti-VEGF Therapies market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Bevacizumab
• Ramucirumab
• Ranibizumab
• Aflibercept
• Conbercept
• Other

Segmentation by Application:

• Hospitals
• Clinics

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Roche
• Eli Lilly
• Pfizer
• Regeneron Pharmaceuticals
• Novartis
• Alphamab Oncology
• Chengdu Kanghong Pharmaceutical

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Anti-VEGF Therapies Market Size (2021-2032)
  2.1.2 Anti-VEGF Therapies Market Size CAGR by Region (2021 VS 2025 VS 2032)
  2.1.3 World Current & Future Analysis for Anti-VEGF Therapies by Country/Region (2021, 2025 & 2032)
2.2 Anti-VEGF Therapies Segment by Type
  2.2.1 Bevacizumab
  2.2.2 Ramucirumab
  2.2.3 Ranibizumab
  2.2.4 Aflibercept
  2.2.5 Conbercept
  2.2.6 Other
  2.2.7 Anti-VEGF Therapies Market Size by Type
    2.2.7.1 Anti-VEGF Therapies Market Size CAGR by Type (2021 VS 2025 VS 2032)
    2.2.7.2 Global Anti-VEGF Therapies Market Size Market Share by Type (2021-2026)
2.3 Anti-VEGF Therapies Segment by Application
  2.3.1 Hospitals
  2.3.2 Clinics
  2.3.3 Anti-VEGF Therapies Market Size by Application
    2.3.3.1 Anti-VEGF Therapies Market Size CAGR by Application (2021 VS 2025 VS 2032)
    2.3.3.2 Global Anti-VEGF Therapies Market Size Market Share by Application (2021-2026)

3 ANTI-VEGF THERAPIES MARKET SIZE BY PLAYER

3.1 Anti-VEGF Therapies Market Size Market Share by Player
  3.1.1 Global Anti-VEGF Therapies Revenue by Player (2021-2026)
  3.1.2 Global Anti-VEGF Therapies Revenue Market Share by Player (2021-2026)
3.2 Global Anti-VEGF Therapies Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 ANTI-VEGF THERAPIES BY REGION

4.1 Anti-VEGF Therapies Market Size by Region (2021-2026)
4.2 Global Anti-VEGF Therapies Annual Revenue by Country/Region (2021-2026)
4.3 Americas Anti-VEGF Therapies Market Size Growth (2021-2026)
4.4 APAC Anti-VEGF Therapies Market Size Growth (2021-2026)
4.5 Europe Anti-VEGF Therapies Market Size Growth (2021-2026)
4.6 Middle East & Africa Anti-VEGF Therapies Market Size Growth (2021-2026)

5 AMERICAS

5.1 Americas Anti-VEGF Therapies Market Size by Country (2021-2026)
5.2 Americas Anti-VEGF Therapies Market Size by Type (2021-2026)
5.3 Americas Anti-VEGF Therapies Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Anti-VEGF Therapies Market Size by Region (2021-2026)
6.2 APAC Anti-VEGF Therapies Market Size by Type (2021-2026)
6.3 APAC Anti-VEGF Therapies Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Anti-VEGF Therapies Market Size by Country (2021-2026)
7.2 Europe Anti-VEGF Therapies Market Size by Type (2021-2026)
7.3 Europe Anti-VEGF Therapies Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Anti-VEGF Therapies by Region (2021-2026)
8.2 Middle East & Africa Anti-VEGF Therapies Market Size by Type (2021-2026)
8.3 Middle East & Africa Anti-VEGF Therapies Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL ANTI-VEGF THERAPIES MARKET FORECAST

10.1 Global Anti-VEGF Therapies Forecast by Region (2027-2032)
  10.1.1 Global Anti-VEGF Therapies Forecast by Region (2027-2032)
  10.1.2 Americas Anti-VEGF Therapies Forecast
  10.1.3 APAC Anti-VEGF Therapies Forecast
  10.1.4 Europe Anti-VEGF Therapies Forecast
  10.1.5 Middle East & Africa Anti-VEGF Therapies Forecast
10.2 Americas Anti-VEGF Therapies Forecast by Country (2027-2032)
  10.2.1 United States Market Anti-VEGF Therapies Forecast
  10.2.2 Canada Market Anti-VEGF Therapies Forecast
  10.2.3 Mexico Market Anti-VEGF Therapies Forecast
  10.2.4 Brazil Market Anti-VEGF Therapies Forecast
10.3 APAC Anti-VEGF Therapies Forecast by Region (2027-2032)
  10.3.1 China Anti-VEGF Therapies Market Forecast
  10.3.2 Japan Market Anti-VEGF Therapies Forecast
  10.3.3 Korea Market Anti-VEGF Therapies Forecast
  10.3.4 Southeast Asia Market Anti-VEGF Therapies Forecast
  10.3.5 India Market Anti-VEGF Therapies Forecast
  10.3.6 Australia Market Anti-VEGF Therapies Forecast
10.4 Europe Anti-VEGF Therapies Forecast by Country (2027-2032)
  10.4.1 Germany Market Anti-VEGF Therapies Forecast
  10.4.2 France Market Anti-VEGF Therapies Forecast
  10.4.3 UK Market Anti-VEGF Therapies Forecast
  10.4.4 Italy Market Anti-VEGF Therapies Forecast
  10.4.5 Russia Market Anti-VEGF Therapies Forecast
10.5 Middle East & Africa Anti-VEGF Therapies Forecast by Region (2027-2032)
  10.5.1 Egypt Market Anti-VEGF Therapies Forecast
  10.5.2 South Africa Market Anti-VEGF Therapies Forecast
  10.5.3 Israel Market Anti-VEGF Therapies Forecast
  10.5.4 Turkey Market Anti-VEGF Therapies Forecast
10.6 Global Anti-VEGF Therapies Forecast by Type (2027-2032)
10.7 Global Anti-VEGF Therapies Forecast by Application (2027-2032)
  10.7.1 GCC Countries Market Anti-VEGF Therapies Forecast

11 KEY PLAYERS ANALYSIS

11.1 Roche
  11.1.1 Roche Company Information
  11.1.2 Roche Anti-VEGF Therapies Product Offered
  11.1.3 Roche Anti-VEGF Therapies Revenue, Gross Margin and Market Share (2021-2026)
  11.1.4 Roche Main Business Overview
  11.1.5 Roche Latest Developments
11.2 Eli Lilly
  11.2.1 Eli Lilly Company Information
  11.2.2 Eli Lilly Anti-VEGF Therapies Product Offered
  11.2.3 Eli Lilly Anti-VEGF Therapies Revenue, Gross Margin and Market Share (2021-2026)
  11.2.4 Eli Lilly Main Business Overview
  11.2.5 Eli Lilly Latest Developments
11.3 Pfizer
  11.3.1 Pfizer Company Information
  11.3.2 Pfizer Anti-VEGF Therapies Product Offered
  11.3.3 Pfizer Anti-VEGF Therapies Revenue, Gross Margin and Market Share (2021-2026)
  11.3.4 Pfizer Main Business Overview
  11.3.5 Pfizer Latest Developments
11.4 Regeneron Pharmaceuticals
  11.4.1 Regeneron Pharmaceuticals Company Information
  11.4.2 Regeneron Pharmaceuticals Anti-VEGF Therapies Product Offered
  11.4.3 Regeneron Pharmaceuticals Anti-VEGF Therapies Revenue, Gross Margin and Market Share (2021-2026)
  11.4.4 Regeneron Pharmaceuticals Main Business Overview
  11.4.5 Regeneron Pharmaceuticals Latest Developments
11.5 Novartis
  11.5.1 Novartis Company Information
  11.5.2 Novartis Anti-VEGF Therapies Product Offered
  11.5.3 Novartis Anti-VEGF Therapies Revenue, Gross Margin and Market Share (2021-2026)
  11.5.4 Novartis Main Business Overview
  11.5.5 Novartis Latest Developments
11.6 Alphamab Oncology
  11.6.1 Alphamab Oncology Company Information
  11.6.2 Alphamab Oncology Anti-VEGF Therapies Product Offered
  11.6.3 Alphamab Oncology Anti-VEGF Therapies Revenue, Gross Margin and Market Share (2021-2026)
  11.6.4 Alphamab Oncology Main Business Overview
  11.6.5 Alphamab Oncology Latest Developments
11.7 Chengdu Kanghong Pharmaceutical
  11.7.1 Chengdu Kanghong Pharmaceutical Company Information
  11.7.2 Chengdu Kanghong Pharmaceutical Anti-VEGF Therapies Product Offered
  11.7.3 Chengdu Kanghong Pharmaceutical Anti-VEGF Therapies Revenue, Gross Margin and Market Share (2021-2026)
  11.7.4 Chengdu Kanghong Pharmaceutical Main Business Overview
  11.7.5 Chengdu Kanghong Pharmaceutical Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Anti-VEGF Therapies Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Anti-VEGF Therapies Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Bevacizumab
Table 4. Major Players of Ramucirumab
Table 5. Major Players of Ranibizumab
Table 6. Major Players of Aflibercept
Table 7. Major Players of Conbercept
Table 8. Major Players of Other
Table 9. Anti-VEGF Therapies Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Anti-VEGF Therapies Market Size by Type (2021-2026) & ($ millions)
Table 11. Global Anti-VEGF Therapies Market Size Market Share by Type (2021-2026)
Table 12. Anti-VEGF Therapies Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 13. Global Anti-VEGF Therapies Market Size by Application (2021-2026) & ($ millions)
Table 14. Global Anti-VEGF Therapies Market Size Market Share by Application (2021-2026)
Table 15. Global Anti-VEGF Therapies Revenue by Player (2021-2026) & ($ millions)
Table 16. Global Anti-VEGF Therapies Revenue Market Share by Player (2021-2026)
Table 17. Anti-VEGF Therapies Key Players Head office and Products Offered
Table 18. Anti-VEGF Therapies Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 19. New Products and Potential Entrants
Table 20. Mergers & Acquisitions, Expansion
Table 21. Global Anti-VEGF Therapies Market Size by Region (2021-2026) & ($ millions)
Table 22. Global Anti-VEGF Therapies Market Size Market Share by Region (2021-2026)
Table 23. Global Anti-VEGF Therapies Revenue by Country/Region (2021-2026) & ($ millions)
Table 24. Global Anti-VEGF Therapies Revenue Market Share by Country/Region (2021-2026)
Table 25. Americas Anti-VEGF Therapies Market Size by Country (2021-2026) & ($ millions)
Table 26. Americas Anti-VEGF Therapies Market Size Market Share by Country (2021-2026)
Table 27. Americas Anti-VEGF Therapies Market Size by Type (2021-2026) & ($ millions)
Table 28. Americas Anti-VEGF Therapies Market Size Market Share by Type (2021-2026)
Table 29. Americas Anti-VEGF Therapies Market Size by Application (2021-2026) & ($ millions)
Table 30. Americas Anti-VEGF Therapies Market Size Market Share by Application (2021-2026)
Table 31. APAC Anti-VEGF Therapies Market Size by Region (2021-2026) & ($ millions)
Table 32. APAC Anti-VEGF Therapies Market Size Market Share by Region (2021-2026)
Table 33. APAC Anti-VEGF Therapies Market Size by Type (2021-2026) & ($ millions)
Table 34. APAC Anti-VEGF Therapies Market Size by Application (2021-2026) & ($ millions)
Table 35. Europe Anti-VEGF Therapies Market Size by Country (2021-2026) & ($ millions)
Table 36. Europe Anti-VEGF Therapies Market Size Market Share by Country (2021-2026)
Table 37. Europe Anti-VEGF Therapies Market Size by Type (2021-2026) & ($ millions)
Table 38. Europe Anti-VEGF Therapies Market Size by Application (2021-2026) & ($ millions)
Table 39. Middle East & Africa Anti-VEGF Therapies Market Size by Region (2021-2026) & ($ millions)
Table 40. Middle East & Africa Anti-VEGF Therapies Market Size by Type (2021-2026) & ($ millions)
Table 41. Middle East & Africa Anti-VEGF Therapies Market Size by Application (2021-2026) & ($ millions)
Table 42. Key Market Drivers & Growth Opportunities of Anti-VEGF Therapies
Table 43. Key Market Challenges & Risks of Anti-VEGF Therapies
Table 44. Key Industry Trends of Anti-VEGF Therapies
Table 45. Global Anti-VEGF Therapies Market Size Forecast by Region (2027-2032) & ($ millions)
Table 46. Global Anti-VEGF Therapies Market Size Market Share Forecast by Region (2027-2032)
Table 47. Global Anti-VEGF Therapies Market Size Forecast by Type (2027-2032) & ($ millions)
Table 48. Global Anti-VEGF Therapies Market Size Forecast by Application (2027-2032) & ($ millions)
Table 49. Roche Details, Company Type, Anti-VEGF Therapies Area Served and Its Competitors
Table 50. Roche Anti-VEGF Therapies Product Offered
Table 51. Roche Anti-VEGF Therapies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 52. Roche Main Business
Table 53. Roche Latest Developments
Table 54. Eli Lilly Details, Company Type, Anti-VEGF Therapies Area Served and Its Competitors
Table 55. Eli Lilly Anti-VEGF Therapies Product Offered
Table 56. Eli Lilly Anti-VEGF Therapies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 57. Eli Lilly Main Business
Table 58. Eli Lilly Latest Developments
Table 59. Pfizer Details, Company Type, Anti-VEGF Therapies Area Served and Its Competitors
Table 60. Pfizer Anti-VEGF Therapies Product Offered
Table 61. Pfizer Anti-VEGF Therapies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 62. Pfizer Main Business
Table 63. Pfizer Latest Developments
Table 64. Regeneron Pharmaceuticals Details, Company Type, Anti-VEGF Therapies Area Served and Its Competitors
Table 65. Regeneron Pharmaceuticals Anti-VEGF Therapies Product Offered
Table 66. Regeneron Pharmaceuticals Anti-VEGF Therapies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 67. Regeneron Pharmaceuticals Main Business
Table 68. Regeneron Pharmaceuticals Latest Developments
Table 69. Novartis Details, Company Type, Anti-VEGF Therapies Area Served and Its Competitors
Table 70. Novartis Anti-VEGF Therapies Product Offered
Table 71. Novartis Anti-VEGF Therapies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 72. Novartis Main Business
Table 73. Novartis Latest Developments
Table 74. Alphamab Oncology Details, Company Type, Anti-VEGF Therapies Area Served and Its Competitors
Table 75. Alphamab Oncology Anti-VEGF Therapies Product Offered
Table 76. Alphamab Oncology Anti-VEGF Therapies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 77. Alphamab Oncology Main Business
Table 78. Alphamab Oncology Latest Developments
Table 79. Chengdu Kanghong Pharmaceutical Details, Company Type, Anti-VEGF Therapies Area Served and Its Competitors
Table 80. Chengdu Kanghong Pharmaceutical Anti-VEGF Therapies Product Offered
Table 81. Chengdu Kanghong Pharmaceutical Anti-VEGF Therapies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 82. Chengdu Kanghong Pharmaceutical Main Business
Table 83. Chengdu Kanghong Pharmaceutical Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Anti-VEGF Therapies Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Anti-VEGF Therapies Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Anti-VEGF Therapies Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Anti-VEGF Therapies Sales Market Share by Country/Region (2025)
Figure 8. Anti-VEGF Therapies Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Anti-VEGF Therapies Market Size Market Share by Type in 2025
Figure 10. Anti-VEGF Therapies in Hospitals
Figure 11. Global Anti-VEGF Therapies Market: Hospitals (2021-2026) & ($ millions)
Figure 12. Anti-VEGF Therapies in Clinics
Figure 13. Global Anti-VEGF Therapies Market: Clinics (2021-2026) & ($ millions)
Figure 14. Global Anti-VEGF Therapies Market Size Market Share by Application in 2025
Figure 15. Global Anti-VEGF Therapies Revenue Market Share by Player in 2025
Figure 16. Global Anti-VEGF Therapies Market Size Market Share by Region (2021-2026)
Figure 17. Americas Anti-VEGF Therapies Market Size 2021-2026 ($ millions)
Figure 18. APAC Anti-VEGF Therapies Market Size 2021-2026 ($ millions)
Figure 19. Europe Anti-VEGF Therapies Market Size 2021-2026 ($ millions)
Figure 20. Middle East & Africa Anti-VEGF Therapies Market Size 2021-2026 ($ millions)
Figure 21. Americas Anti-VEGF Therapies Value Market Share by Country in 2025
Figure 22. United States Anti-VEGF Therapies Market Size Growth 2021-2026 ($ millions)
Figure 23. Canada Anti-VEGF Therapies Market Size Growth 2021-2026 ($ millions)
Figure 24. Mexico Anti-VEGF Therapies Market Size Growth 2021-2026 ($ millions)
Figure 25. Brazil Anti-VEGF Therapies Market Size Growth 2021-2026 ($ millions)
Figure 26. APAC Anti-VEGF Therapies Market Size Market Share by Region in 2025
Figure 27. APAC Anti-VEGF Therapies Market Size Market Share by Type (2021-2026)
Figure 28. APAC Anti-VEGF Therapies Market Size Market Share by Application (2021-2026)
Figure 29. China Anti-VEGF Therapies Market Size Growth 2021-2026 ($ millions)
Figure 30. Japan Anti-VEGF Therapies Market Size Growth 2021-2026 ($ millions)
Figure 31. South Korea Anti-VEGF Therapies Market Size Growth 2021-2026 ($ millions)
Figure 32. Southeast Asia Anti-VEGF Therapies Market Size Growth 2021-2026 ($ millions)
Figure 33. India Anti-VEGF Therapies Market Size Growth 2021-2026 ($ millions)
Figure 34. Australia Anti-VEGF Therapies Market Size Growth 2021-2026 ($ millions)
Figure 35. Europe Anti-VEGF Therapies Market Size Market Share by Country in 2025
Figure 36. Europe Anti-VEGF Therapies Market Size Market Share by Type (2021-2026)
Figure 37. Europe Anti-VEGF Therapies Market Size Market Share by Application (2021-2026)
Figure 38. Germany Anti-VEGF Therapies Market Size Growth 2021-2026 ($ millions)
Figure 39. France Anti-VEGF Therapies Market Size Growth 2021-2026 ($ millions)
Figure 40. UK Anti-VEGF Therapies Market Size Growth 2021-2026 ($ millions)
Figure 41. Italy Anti-VEGF Therapies Market Size Growth 2021-2026 ($ millions)
Figure 42. Russia Anti-VEGF Therapies Market Size Growth 2021-2026 ($ millions)
Figure 43. Middle East & Africa Anti-VEGF Therapies Market Size Market Share by Region (2021-2026)
Figure 44. Middle East & Africa Anti-VEGF Therapies Market Size Market Share by Type (2021-2026)
Figure 45. Middle East & Africa Anti-VEGF Therapies Market Size Market Share by Application (2021-2026)
Figure 46. Egypt Anti-VEGF Therapies Market Size Growth 2021-2026 ($ millions)
Figure 47. South Africa Anti-VEGF Therapies Market Size Growth 2021-2026 ($ millions)
Figure 48. Israel Anti-VEGF Therapies Market Size Growth 2021-2026 ($ millions)
Figure 49. Turkey Anti-VEGF Therapies Market Size Growth 2021-2026 ($ millions)
Figure 50. GCC Countries Anti-VEGF Therapies Market Size Growth 2021-2026 ($ millions)
Figure 51. Americas Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 52. APAC Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 53. Europe Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 54. Middle East & Africa Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 55. United States Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 56. Canada Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 57. Mexico Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 58. Brazil Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 59. China Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 60. Japan Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 61. Korea Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 62. Southeast Asia Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 63. India Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 64. Australia Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 65. Germany Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 66. France Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 67. UK Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 68. Italy Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 69. Russia Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 70. Egypt Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 71. South Africa Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 72. Israel Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 73. Turkey Anti-VEGF Therapies Market Size 2027-2032 ($ millions)
Figure 74. Global Anti-VEGF Therapies Market Size Market Share Forecast by Type (2027-2032)
Figure 75. Global Anti-VEGF Therapies Market Size Market Share Forecast by Application (2027-2032)
Figure 76. GCC Countries Anti-VEGF Therapies Market Size 2027-2032 ($ millions)